6533b835fe1ef96bd129feaa
RESEARCH PRODUCT
The Development of Vaccines from Synthetic Tumor‐Associated Mucin Glycopeptides and their Glycosylation‐Dependent Immune Response
Pol BeseniusMoritz UrschbachEdgar SchmittNatascha StergiouHorst KunzAdele Gabbasubject
GlycosylationGlycosylationGeneral Chemical Engineeringmedicine.medical_treatmentBiologyCancer VaccinesBiochemistryEpitope03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemAntigenNeoplasmsMaterials ChemistrymedicineHumansMUC1030304 developmental biologyVaccines Synthetic0303 health sciencesMucinGlycopeptidesImmunityMucinsGeneral ChemistryImmunotherapy3. Good healthchemistry030220 oncology & carcinogenesisImmunologyAdjuvantdescription
Tumor-associated carbohydrate antigens are overexpressed as altered-self in most common epithelial cancers. Their glycosylation patterns differ from those of healthy cells, functioning as an ID for cancer cells. Scientists have been developing anti-cancer vaccines based on mucin glycopeptides, yet the interplay of delivery system, adjuvant and tumor associated MUC epitopes in the induced immune response is not well understood. The current state of the art suggests that the identity, abundancy and location of the glycans on the MUC backbone are all key parameters in the cellular and humoral response. This review shares lessons learned by us in over two decades of research in glycopeptide vaccines. By bridging synthetic chemistry and immunology, we discuss efforts in designing synthetic MUC1/4/16 vaccines and focus on the role of glycosylation patterns. We provide a brief introduction into the mechanisms of the immune system and aim to promote the development of cancer subunit vaccines.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-10-31 | The Chemical Record |